Evidence map›Paper›PMID 40978150›Full record

ArticleiScience2025

Mitochondrial methylcytosines as blood-based biomarkers for Alzheimer's disease dementia prognosis.

Jordi Gascón-Bayarri, Jose Luis Mosquera, Marta Blanch, Pau Martí, Beatriz Fontal, Carla Trapero, Nuria Rojo, Inma Rico, Jaume Campdelacreu, Cristopher Fowler and 10 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in iScience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Jordi Gascón-BayarriFunctional Unit of Dementia, Service of Neurology, Bellvitge University Hospital, Bellvitge Biomedical Research Institute, IDIBELL, 08907 Barcelona, Spain.
Jose Luis MosqueraADmit Therapeutics SL, 08980 Barcelona, Spain.
Marta BlanchADmit Therapeutics SL, 08980 Barcelona, Spain.
Pau MartíADmit Therapeutics SL, 08980 Barcelona, Spain.
Beatriz FontalADmit Therapeutics SL, 08980 Barcelona, Spain.
Carla TraperoADmit Therapeutics SL, 08980 Barcelona, Spain.
Nuria RojoFunctional Unit of Dementia, Service of Neurology, Bellvitge University Hospital, Bellvitge Biomedical Research Institute, IDIBELL, 08907 Barcelona, Spain.
Inma RicoFunctional Unit of Dementia, Service of Neurology, Bellvitge University Hospital, Bellvitge Biomedical Research Institute, IDIBELL, 08907 Barcelona, Spain.
Jaume CampdelacreuFunctional Unit of Dementia, Service of Neurology, Bellvitge University Hospital, Bellvitge Biomedical Research Institute, IDIBELL, 08907 Barcelona, Spain.
Cristopher FowlerThe Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Melbourne, VIC 3010, Australia.
Simon M LawsCollaborative Genomics and Translation Group, Centre for Precision Health, School of Medical and Health Sciences, Edith Cowan University, Joondalup, WA 6027, Australia.
Adrià Tort-MerinoAlzheimer's Disease and Other Cognitive Disorders Unit, Neurology Service, Hospital Clínic de Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona, 08036 Barcelona, Spain.
Raquel Sanchez-ValleAlzheimer's Disease and Other Cognitive Disorders Unit, Neurology Service, Hospital Clínic de Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona, 08036 Barcelona, Spain.
Joan BelloNeurology Service, Complex Hospitalari Moisès Broggi, 08906 L'Hospitalet/Sant Joan Despí, Spain.
Juan ForteaCentro de Investigación Biomédica en Red en Enfermedades Neurodegenerativas (CIBERNED), 28029 Madrid, Spain.
Alberto LleóCentro de Investigación Biomédica en Red en Enfermedades Neurodegenerativas (CIBERNED), 28029 Madrid, Spain.
Courosh MehanianGlobal Health Labs, Bellevue, WA 98007, USA.
Russell H SwerdlowThe University of Kansas Alzheimer's Disease Research Center, Fairway, KS 66205, USA.
Ramón Reñé-RamírezFunctional Unit of Dementia, Service of Neurology, Bellvitge University Hospital, Bellvitge Biomedical Research Institute, IDIBELL, 08907 Barcelona, Spain.
Marta BarrachinaADmit Therapeutics SL, 08980 Barcelona, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Alzheimer's Disease Dementia (ADD) prognosis is an unmet medical need. Mitochondrial dysfunction is an early AD etiopathogenic factor. The present study analyzed mitochondrial DNA (mtDNA) methylation patterns in blood samples from patients with mild cognitive impairment (MCI) who progressed to ADD (P), MCI remained stable (NP), and Cognitively Normal (CN) individuals. Differentially methylated sites were identified in the D-loop region in both CN vs. NP and NP vs. P comparisons, even before β-amyloid positivity. A Random Forest model was developed using mtDNA methylation data combined with cognitive and risk factor features. Model's performance was assessed by cross-validation and tested on an independent set, achieving 84.4% accuracy in training and 83.2% (95% CI: 75.2%-89.4%) in testing. For identifying P patients, sensitivity and specificity were 95.1% and 70.7%, respectively. The AUC-ROC was 90.3%. The developed model demonstrates predictive capacity in distinguishing cognitive decline and stability in MCI individuals, independently of their β-amyloid status.

Indexed as

medicinemolecular neuroscienceneurologyneuroscience

Identifiers

PMID40978150
PMCPMC12448035

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.